Is a complete JANX research report available?

No complete published report is available for Janux Therapeutics, Inc. (JANX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Janux Therapeutics, Inc. (JANX)

NASDAQ: JANX · USD

$18.0

+0.77 (+4.5%)· Recorded snapshot

Market cap	1.1B
Revenue (ttm)	24M
Net income (ttm)	-102.6M
EPS (ttm)	-$1.64
Shares out	61.1M
Volume	850,062
Beta	2.39

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 24M
Net income (ttm): -102.6M
EPS (ttm): -$1.64
Market cap: 1.1B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Conserver

Metric	Value
Amount currency	USD
CIK code	0001817713
Company name	Janux Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	47103J105
Earnings date	2026-11-09
Earnings time	amc
Employees	113
Employees change	10
Employees growth	9.71%
Enterprise value	$152.4M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2017
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2021-06-11
Is primary listing	Yes
Is SPAC	No
ISIN number	US47103J1051
Last 10-K release date	2026-02-26
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$1.1B
Market cap category	Small-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$18.03
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	JANX
U.S. state	California
Website	https://www.januxrx.com

Metric

Value

Amount currency

USD

CIK code

0001817713

Company name

Janux Therapeutics, Inc.

Country

United States

Country code

CUSIP number

47103J105

Earnings date

2026-11-09

Earnings time

amc

Employees

113

Employees change

Employees growth

9.71%

Enterprise value

$152.4M

Exchange

NASDAQ

Financial currency

USD

Financial report date

2026-06-30

First seen

2026-05-09

Fiscal year end

December

Founded

2017

In index

RUSSELL2000

Industry

Biotechnology

IPO date

2021-06-11

Is primary listing

Yes

Is SPAC

ISIN number

US47103J1051

Last 10-K release date

2026-02-26

Last earnings date

2026-08-06

Last refreshed

2026-10-28

Last stock split type

Never

Market cap

$1.1B

Market cap category

Small-Cap

Next earnings date

2026-11-09

Options

Yes

Price

$18.03

Price currency

USD

Sector

Healthcare

SIC code

2834

Stock price date

2026-10-28

Symbol

JANX

U.S. state

California

Website

https://www.januxrx.com

Metric	Value
Earnings yield	-9.11%
EV/Sales	5.33x
FCF / EV yield	-32.77%
FCF yield	-3.89%
Forward EV/Sales	6.86x
Forward P/S	57.8x
P/B ratio	1.14x
P/S ratio	44.91x
Price / tangible book value	1.16x
Sector forward P/E	23.56x
Sector P/E	50.13x

Metric

Value

Earnings yield

-9.11%

EV/Sales

5.33x

FCF / EV yield

-32.77%

FCF yield

-3.89%

Forward EV/Sales

6.86x

Forward P/S

57.8x

P/B ratio

1.14x

P/S ratio

44.91x

Price / tangible book value

1.16x

Sector forward P/E

23.56x

Sector P/E

50.13x

Metric	Value
Operating margin	-598.15%
Pretax margin	-427.47%
Profit per employee	$-907,894
Revenue per employee	$212,389
ROA	-8.8%
ROA (5Y)	-10.41%
ROCE	-15.15%
ROE	-10.7%
ROE (5Y)	-14.99%
ROIC	-9.15%
SBC / revenue	153.71%

Metric

Value

Operating margin

-598.15%

Pretax margin

-427.47%

Profit per employee

$-907,894

Revenue per employee

$212,389

ROA

-8.8%

ROA (5Y)

-10.41%

ROCE

-15.15%

ROE

-10.7%

ROE (5Y)

-14.99%

ROIC

-9.15%

SBC / revenue

153.71%

Metric	Value
EPS growth quarters	1
EPS growth years	0
Net income growth quarters	1
Net income growth years	0
Revenue growth	5,366.97%
Revenue growth (QoQ)	175.03%
Revenue growth 3Y	45.68%
Revenue growth 5Y	94.51%
Revenue growth years	0

Metric

Value

EPS growth quarters

EPS growth years

Net income growth quarters

Net income growth years

Revenue growth

5,366.97%

Revenue growth (QoQ)

175.03%

Revenue growth 3Y

45.68%

Revenue growth 5Y

94.51%

Revenue growth years

Metric	Value
Capital expenditures	$-674,000
Depreciation and amortization	$1.9M
EBIT	$-143.6M
EBITDA	$-141.7M
EPS	$-1.64
FCF per share	$-0.69
Financing cash flow	$9.2M
Free cash flow	$-41.9M
Free cash flow minus SBC	$-78.8M
Gross profit	$-100M
Investing cash flow	$7.4M
Net cash flow	$-24.7M
Net income	$-102.6M
Operating cash flow minus SBC	$-78.1M
Operating income	$-143.6M
Revenue	$24M
Stock-based compensation	$36.9M

Metric

Value

Capital expenditures

$-674,000

Depreciation and amortization

$1.9M

EBIT

$-143.6M

EBITDA

$-141.7M

EPS

$-1.64

FCF per share

$-0.69

Financing cash flow

$9.2M

Free cash flow

$-41.9M

Free cash flow minus SBC

$-78.8M

Gross profit

$-100M

Investing cash flow

$7.4M

Net cash flow

$-24.7M

Net income

$-102.6M

Operating cash flow minus SBC

$-78.1M

Operating income

$-143.6M

Revenue

$24M

Stock-based compensation

$36.9M

Metric	Value
Altman Z-Score	8.77
Book value per share	$15.19
Debt / equity	0.02
Long-term assets	$24.3M
Long-term liabilities	$19.5M
Net cash (debt)	$949.9M
Net cash / market cap	88.13%
Net cash growth	-2.45%
Net debt / equity	-1.02
Piotroski F-Score	3
Property, plant and equipment	$20.6M
Shareholders' equity	$928M
Tangible book value	$928M
Tangible book value per share	$15.19
Total assets	$1B
Total cash	$970.9M
Total debt	$21M
Total liabilities	$79.7M
WACC	17.07%

Metric

Value

Altman Z-Score

8.77

Book value per share

$15.19

Debt / equity

0.02

Long-term assets

$24.3M

Long-term liabilities

$19.5M

Net cash (debt)

$949.9M

Net cash / market cap

88.13%

Net cash growth

-2.45%

Net debt / equity

-1.02

Piotroski F-Score

Property, plant and equipment

$20.6M

Shareholders' equity

$928M

Tangible book value

$928M

Tangible book value per share

$15.19

Total assets

$1B

Total cash

$970.9M

Total debt

$21M

Total liabilities

$79.7M

WACC

17.07%

Metric	Value
Asset turnover	0.02
Current assets	$983.3M
Current liabilities	$60.2M
Current ratio	16.35
Net working capital	$-45.2M
Quick ratio	16.25
Working capital	$923.2M
Working capital turnover	0.03

Metric

Value

Asset turnover

0.02

Current assets

$983.3M

Current liabilities

$60.2M

Current ratio

16.35

Net working capital

$-45.2M

Quick ratio

16.25

Working capital

$923.2M

Working capital turnover

0.03

Metric	Value
Buyback yield / dilution	-6.2%
Dividend yield	0%
Shareholder yield	-6.2%

Metric

Value

Buyback yield / dilution

-6.2%

Dividend yield

Shareholder yield

-6.2%

Metric	Value
150-day SMA	$15.81
1D price change	4.46%
1M price change	9.33%
1M total return	9.33%
1W price change	3.61%
1W total return	3.61%
1Y price change	-34.84%
1Y return CAGR	-34.86%
1Y total return	-34.84%
20-day SMA	$17.23
200-day SMA	$15.29
3M price change	14.45%
3M total return	14.45%
3Y price change	196.01%
3Y return CAGR	43.57%
3Y total return	196.01%
50-day SMA	$17.58
50-day SMA vs 200-day SMA	50over200
52-week high	$35.34
52-week high date	2025-11-26
52-week low	$12.12
52-week low date	2026-02-05
5Y price change	-25.53%
5Y return CAGR	-5.73%
5Y total return	-25.53%
6M price change	17.01%
6M total return	17.01%
All-time high	$71.71
All-time high date	2024-12-05
All-time low	$5.65
All-time low date	2023-11-10
Average true range (ATR)	$0.83
Average volume	764.8K
Beta (1Y)	1.78
Beta (2Y)	1.2
Beta (5Y)	2.39
Change from 52-week high	-48.98%
Change from 52-week low	48.76%
Change from all-time high	-75.15%
Change from all-time low	215.4%
Change from open	4.22%
Day's gap	0.23%
Dollar volume	$15.3M
High price	$18.06
Low price	$17.15
Monthly RSI	45.18
Open price	$17.30
Position in 52-week range	96.7%
Previous close	$17.26
Price vs 150-day SMA	12.69%
Price vs 20-day SMA	3.4%
Price vs 200-day SMA	16.55%
Price vs 50-day SMA	1.35%
Relative volume	1.11
Return from IPO open	-48.15%
Return from IPO price	3.71%
RSI	55.99
Sharpe ratio	-0.18
Sharpe ratio (3Y)	0.63
Sharpe ratio (5Y)	0.35
Sortino ratio	-0.14
Sortino ratio (3Y)	1.96
Sortino ratio (5Y)	0.92
Volume	850.1K
Weekly RSI	54.18
YTD price change	29.13%
YTD total return	29.13%

Metric

Value

150-day SMA

$15.81

1D price change

4.46%

1M price change

9.33%

1M total return

9.33%

1W price change

3.61%

1W total return

3.61%

1Y price change

-34.84%

1Y return CAGR

-34.86%

1Y total return

-34.84%

20-day SMA

$17.23

200-day SMA

$15.29

3M price change

14.45%

3M total return

14.45%

3Y price change

196.01%

3Y return CAGR

43.57%

3Y total return

196.01%

50-day SMA

$17.58

50-day SMA vs 200-day SMA

50over200

52-week high

$35.34

52-week high date

2025-11-26

52-week low

$12.12

52-week low date

2026-02-05

5Y price change

-25.53%

5Y return CAGR

-5.73%

5Y total return

-25.53%

6M price change

17.01%

6M total return

17.01%

All-time high

$71.71

All-time high date

2024-12-05

All-time low

$5.65

All-time low date

2023-11-10

Average true range (ATR)

$0.83

Average volume

764.8K

Beta (1Y)

1.78

Beta (2Y)

1.2

Beta (5Y)

2.39

Change from 52-week high

-48.98%

Change from 52-week low

48.76%

Change from all-time high

-75.15%

Change from all-time low

215.4%

Change from open

4.22%

Day's gap

0.23%

Dollar volume

$15.3M

High price

$18.06

Low price

$17.15

Monthly RSI

45.18

Open price

$17.30

Position in 52-week range

96.7%

Previous close

$17.26

Price vs 150-day SMA

12.69%

Price vs 20-day SMA

3.4%

Price vs 200-day SMA

16.55%

Price vs 50-day SMA

1.35%

Relative volume

1.11

Return from IPO open

-48.15%

Return from IPO price

3.71%

RSI

55.99

Sharpe ratio

-0.18

Sharpe ratio (3Y)

0.63

Sharpe ratio (5Y)

0.35

Sortino ratio

-0.14

Sortino ratio (3Y)

1.96

Sortino ratio (5Y)

0.92

Volume

850.1K

Weekly RSI

54.18

YTD price change

29.13%

YTD total return

29.13%

Metric	Value
Float	42.5M
Float percentage	69.56%
Shares change (QoQ)	0.43%
Shares change (YoY)	6.2%
Shares held by insiders	5.92%
Shares held by institutions	77.14%
Shares outstanding	61.1M
Short % of float	13.37%
Short % of shares	9.3%
Short ratio	5.8 days

Metric

Value

Float

42.5M

Float percentage

69.56%

Shares change (QoQ)

0.43%

Shares change (YoY)

6.2%

Shares held by insiders

5.92%

Shares held by institutions

77.14%

Shares outstanding

61.1M

Short % of float

13.37%

Short % of shares

9.3%

Short ratio

5.8 days

Janux Therapeutics, Inc. (JANX)

Price

Financial snapshot

Fair-value bridge

Latest news · JANX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All JANX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on JANX

Frequently asked questions